Walleye Capital
AVIR icon

Walleye Capital’s Atea Pharmaceuticals AVIR Stock Holding History

Walleye Capital’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-57,759
Closed -$208K – 4478
2025
Q2 		$208K Buy
+57,759
New +$172K ﹤0.01% 3342
2022
Q1 		– Sell
-124,973
Closed -$1.12M – 2282
2021
Q4 		$1.12M Buy
+124,973
New +$1.95M 0.03% 523

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's AVIR Position: Q3 2025 in Review

Walleye Capital sold out of Atea Pharmaceuticals (AVIR) in Q3 2025, closing a stake of 57,759 shares — an estimated $208K sold.

Walleye Capital first reported a position in AVIR in Q4 2021 and held it in 2 quarters. The position peaked at $1.12M in Q4 2021. 115 funds tracked by Wall St. Rank hold AVIR as of Q3 2025.

  • Walleye Capital reported no remaining Atea Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 57,759 Atea Pharmaceuticals shares in Q3 2025, an estimated $208K.
  • Walleye Capital first reported a position in Atea Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Walleye Capital's Atea Pharmaceuticals position peaked at $1.12M in Q4 2021.
  • 115 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.